Review: The biological basis of antipsychotic response in schizophrenia.
Schizophrenia is a severe mental illness affecting approximately 1% of the population worldwide. Antipsychotic drugs are effective in symptom control in up to two-thirds of patients, but in at least one-third of patients the response is poor. The reason for this is not clear, but one possibility is that good and poor responders have different neurochemical pathologies, and may therefore benefit from different treatment approaches. In this selective review we summarise research findings investigating the biological differences between patients with schizophrenia who show a good or a poor response to treatment with antipsychotic drugs.
Stone
James M
JM
Institute of Psychiatry, King's College London, London SE5 8AF, UK. james.stone@iop.kcl.ac.uk
Raffin
Marie
M
Morrison
Paul
P
McGuire
Philip K
PK
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D001921:Brain / Q000473:pathology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*
D014150:Antipsychotic Agents; D015415:Biomarkers